EN DE
Watch FutureChem Co.Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

FutureChem Co.Ltd (220100) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of FutureChem Co.Ltd stock KRW 4,968, price KRW 6,510, that is 23.7% below the price, quality 42 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7220100002

FC FutureChem Co.Ltd logo Thin data Nov 10, 2026

FutureChem Co.Ltd

220100 · KQ
Expensive, weak quality

Our calculation puts a fair price 24% below what the stock costs today.

Low debt
Revenue last quarter +17% vs. a year ago.
Quality 42/100
Expensive Growth (revenue 5y +11.1 %/yr in KRW)
Fair value 4,968 KRW · Overvalued
Loss-making · -54.1% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 12/100
Thin data
Estimate
Watch FutureChem Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

27,569 KRW 5,151 KRW Fair Value 4,968 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 5,151 KRW – 27,569 KRW · fair‑value band 3,726 KRW – 6,210 KRW · the 6,510 KRW price screens above the 4,968 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow FutureChem Co.Ltd in your weekly email

Every Wednesday you see whether FutureChem Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally.

Show moreShow less

The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis.

Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of prostate cancer; F-FMT for brain tumor diagnosis; FC-505 for the treatment of arteriosclerosis and myocardial infarction; FC-211 for Alzheimer's disease; FC-2 for the treatment of hypoxia; FC-3 for solid cancer; FC801 for bladder cancer; and FC901 for the treatment of pulmonary fibrosis.

The company also provides automatic synthesis equipment, such as sCUBE-RXN (synthetic), sCUBE-P&F (tablet-formulation), and sCUBE-M (radioactive, metal).

In addition, it offers molecular imaging device airway sleeve and disposable cartridges, as well as engages in medical device wholesale and healthcare business. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.

Stock analysis

FutureChem Co.Ltd (220100) currently trades at 6,510 KRW, while our estimate is 4,968 KRW, 24% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 3,726 KRW (bear) to 6,210 KRW (bull), the price of 6,510 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

FutureChem Co.Ltd reported revenue of 18.7B KRW in FY2025 versus 11.8B KRW in FY2021, a compound +12.1%/yr. Reported net income was −11.3B KRW in FY2025.

Key figures

Market cap 186B KRW (≈ $139M) Micro · P/S ratio 9.61 · EPS (TTM) −396.53 KRW · Net margin −54.1% · Return on equity −19.0% · Return on assets (EBIT) −11.9% (5-year average) · Operating margin −75.4% · Revenue (TTM) 20.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 76% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −24%, 220100 screens cheaper than that median.

Fair Value

Bear 3,726 KRW Fair Value 4,968 KRW Bull 6,210 KRW
Price 6,510 KRW · Downside -23.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 46
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+8.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Start year 2020 (pandemic). Over 10 years: +29.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−44.4% (2020) → −41.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

220100 screens overvalued: fair value 24% below the price. Compare with Merck KGaA →

Compare FutureChem Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −23.7% · Below median
Profitability
Return on assets −15.1% · Bottom 25%
Net margin (12 months) −54.1% · Bottom 25%
Operating margin (12 months) −75.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 17.4% · Above median
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 3.40× · Priciest 25%
P/S (12 months) 9.03× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)2 · sector 18
FUTURE (revenue growth)87 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs 220100
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs 220100
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs 220100
Haleon plc HLN $9.06 $8.62 −5% vs 220100
Merck KGaA MRK €149.35 €109.18 −27% vs 220100
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs 220100
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs 220100
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs 220100
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs 220100
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 220100

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

FutureChem Co.Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "FutureChem Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/220100

Frequently asked questions

Is FutureChem Co.Ltd (220100) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 4,968 KRW versus a price of 6,510 KRW, about 24% lower (overvalued).
What is the fair value of 220100?
Our estimate for FutureChem Co.Ltd is 4,968 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 6,510 KRW.
What is the quality score of 220100?
FutureChem Co.Ltd has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for FutureChem Co.Ltd (220100)?
Our calculated price target is the estimate of 4,968 KRW (as of Nov 10, 2026). Cautious scenario 3,726 KRW, optimistic scenario 6,210 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the FutureChem Co.Ltd stock forecast for 2026?
Our estimate puts fair value at 4,968 KRW, about 24% lower versus a price of 6,510 KRW (overvalued). Cautious scenario 3,726 KRW, optimistic scenario 6,210 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of FutureChem Co.Ltd (220100)?
FutureChem Co.Ltd reported trailing-twelve-month revenue of about 20.6B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of FutureChem Co.Ltd (220100)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For FutureChem Co.Ltd it is 4,968 KRW per share (as of Nov 10, 2026), against a price of 6,510 KRW.
Is FutureChem Co.Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 220100 trades above its calculated fair value: price 6,510 KRW, fair value 4,968 KRW, a gap of about −24% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 220100?
No. The price is what the market pays today (6,510 KRW); the fair value is what the company's own numbers justify (4,968 KRW). For FutureChem Co.Ltd the two are 1,542 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is FutureChem Co.Ltd worth?
The market values FutureChem Co.Ltd at about 186B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 6,510 KRW; our models calculate a fair value of 4,968 KRW per share.
What do the bullish and bearish scenarios say about 220100?
Our models span a range for FutureChem Co.Ltd: cautious scenario 3,726 KRW, base 4,968 KRW, optimistic 6,210 KRW per share (as of Nov 10, 2026, price 6,510 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of FutureChem Co.Ltd (220100)?
Balance-sheet figures for FutureChem Co.Ltd (as of Nov 10, 2026): return on equity −19.0%, debt of 0.05 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 220100 from its 52-week high?
FutureChem Co.Ltd trades at 6,510 KRW, about 76% below its 52-week high of 27,569 KRW and 13% above the low of 5,758 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 4,968 KRW is for.
Which stocks are comparable to FutureChem Co.Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is FutureChem Co.Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 6,510 KRW, calculated fair value 4,968 KRW (−24%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. FutureChem Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of FutureChem Co.Ltd (220100)?
The closing price on Nov 10, 2026 was 6,510 KRW. Our estimate is 4,968 KRW, about 24% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with FutureChem Co.Ltd right now?
The price sits above even our optimistic bull case (6,210 KRW). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of FutureChem Co.Ltd

How large is the market capitalisation of FutureChem Co.Ltd (220100)?
The market capitalisation of FutureChem Co.Ltd is 186B KRW (≈ $139M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of FutureChem Co.Ltd (220100)?
The price-to-sales ratio of FutureChem Co.Ltd is 9.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of FutureChem Co.Ltd (220100)?
Earnings per share at FutureChem Co.Ltd are −396.53 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of FutureChem Co.Ltd (220100)?
The net margin of FutureChem Co.Ltd is −54.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of FutureChem Co.Ltd (220100)?
The return on equity (ROE) of FutureChem Co.Ltd is −19.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of FutureChem Co.Ltd (220100)?
On an EBIT basis the return on assets of FutureChem Co.Ltd is −11.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of FutureChem Co.Ltd (220100)?
The operating margin of FutureChem Co.Ltd is −75.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at FutureChem Co.Ltd (220100)?
Revenue at FutureChem Co.Ltd is growing +17.4% versus a year earlier (3y avg +14.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at FutureChem Co.Ltd (220100)?
Earnings per share at FutureChem Co.Ltd are growing −10.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does FutureChem Co.Ltd (220100) generate?
The free cash flow of FutureChem Co.Ltd is −11.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does FutureChem Co.Ltd (220100) carry?
The net debt of FutureChem Co.Ltd is 5.9B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch FutureChem Co.Ltd in the live analysis

One click puts FutureChem Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.